Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of repeated ertumaxomab dosing in HER2-low advanced or metastatic breast cancer
2006-005017-36Phase 2Terminated
- Sponsor
- Fresenius
- Start
- Dec 2006
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ertumaxomab in breast cancer, sponsored by Fresenius. Primary endpoint: Objective response rate. Started Dec 2006; status: terminated.
02
Drugs
ertumaxomab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-005017-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005017-36.